Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.
Brianna Lutz, MSN, RN, OCN, discusses a red-and-green dot hourly column that shows which patients with cancer have been attended to in the past hour.
Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.
Bendamustine plus obinutuzumab outperformed historical data of bendamustine plus rituximab for patients with treatment naïve mantle cell lymphoma.
The gift is from the estate of Tom and Catherine Culley, longtime residents of the East Coast and worldwide travelers.
One expert wrote that through education, prevention, and support, oncology nurses may play a role in reducing health inequities in melanoma.
Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.
Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.
Wilderness therapy is a nontraditional form of therapy that uses components of exposure to outdoor activity and mental health treatment.
Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.
Janelle Wagner, RN, OCN, Senior Manager of Patient Navigation Program for Community Sites, highlights some challenges commonly associated with nurse navigation, and how nurses can overcome them.
Kate Sandstrom, MSN, APRN-BC, AOCN, discusses the importance of including the radiation oncology team in a patient’s long-term care plan.
Nurses treating patients with MPNs should remember to advocate for and empower them.
A tiered level preceptor recognition program offers a cost-effective organizational intervention designed to acknowledge and incentivize the contributions of advanced practice preceptors.
The panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Patients insured by Medicare can now receive coverage for lymphedema compression garments as a result of the Lymphedema Treatment Act, but it is essential that oncology nurses communicate this with their patients.
It is anticipated that health care spending will grow by an annual average of 5.4% over the next 8 years.
The program’s initiative aims to identify those at increased risk for cancer through assessment and testing and then formulate a personalized evidence-based cancer surveillance or screening plan.
Kathy Burns, MS, APRN-CNS, AGCNS-BC, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, comments on the importance of self-awareness as an oncology nurse when working to overcome one’s implicit bias.
Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.
Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.
An oncology nurse's experience with her mother's cancer and her own BRCA2 diagnosis shapes her approach to patient care.
Within this intense experience, caregivers can often find themselves physically and emotionally exhausted
Oncology nurses are in a unique position to educate patients with breast cancer about post-mastectomy chest numbness.
An expert with the phase 1b TRIMM-2 trial underscores the significance and findings for patients with multiple myeloma.
AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN, discusses her research on plastic-backed pads and discusses the importance of better methods to reduce exposure to antineoplastic drug residue.
The APRN position has an important, albeit recent, history.
An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer treated with pralsetinib.